Thrombocytosis Treatment: Risk-Stratified Approach Based on Etiology

Primary vs. Secondary Thrombocytosis

  • Reactive (Secondary): Infection, inflammation, iron deficiency, splenectomy, rebound. Treat the underlying cause; platelets normalize. Thrombotic risk is low.
  • Clonal (Primary/Myeloproliferative): Essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), CML. Requires disease-specific therapy.

Management by Risk (Essential Thrombocythemia Example)

Risk CategoryCriteriaTherapy
Low<60 years, no thrombosis, JAK2−Observation ± low-dose aspirin
Intermediate>60 years or JAK2+Aspirin + cytoreduction (hydroxyurea)
HighPrior thrombosisAspirin + hydroxyurea ± interferon-α

Other MPNs

  • PV: Phlebotomy (Hct <45% men, <42% women) + aspirin ± hydroxyurea.
  • CML: TKI (imatinib, nilotinib).
  • PMF: JAK inhibitor (ruxolitinib) for symptoms/splenomegaly.

Extreme Thrombocytosis (>1,000–1,500×10⁹/L)

Acquired von Willebrand syndrome → bleeding risk. Plateletpheresis for acute symptoms; urgent cytoreduction.

Blood Disorders - Related Articles